1. Home
  2. SCYX vs EPOW Comparison

SCYX vs EPOW Comparison

Compare SCYX & EPOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • EPOW
  • Stock Information
  • Founded
  • SCYX 1999
  • EPOW 2014
  • Country
  • SCYX United States
  • EPOW China
  • Employees
  • SCYX N/A
  • EPOW N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • EPOW Business Services
  • Sector
  • SCYX Health Care
  • EPOW Consumer Discretionary
  • Exchange
  • SCYX Nasdaq
  • EPOW Nasdaq
  • Market Cap
  • SCYX 28.5M
  • EPOW 24.8M
  • IPO Year
  • SCYX 2014
  • EPOW 2021
  • Fundamental
  • Price
  • SCYX $0.70
  • EPOW $0.90
  • Analyst Decision
  • SCYX
  • EPOW
  • Analyst Count
  • SCYX 0
  • EPOW 0
  • Target Price
  • SCYX N/A
  • EPOW N/A
  • AVG Volume (30 Days)
  • SCYX 187.5K
  • EPOW 16.4K
  • Earning Date
  • SCYX 08-11-2025
  • EPOW 08-05-2025
  • Dividend Yield
  • SCYX N/A
  • EPOW N/A
  • EPS Growth
  • SCYX N/A
  • EPOW N/A
  • EPS
  • SCYX N/A
  • EPOW N/A
  • Revenue
  • SCYX $2,630,000.00
  • EPOW $64,997,741.00
  • Revenue This Year
  • SCYX $410.22
  • EPOW N/A
  • Revenue Next Year
  • SCYX $248.83
  • EPOW N/A
  • P/E Ratio
  • SCYX N/A
  • EPOW N/A
  • Revenue Growth
  • SCYX N/A
  • EPOW 44.28
  • 52 Week Low
  • SCYX $0.66
  • EPOW $0.55
  • 52 Week High
  • SCYX $2.21
  • EPOW $1.36
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 41.70
  • EPOW 46.09
  • Support Level
  • SCYX $0.67
  • EPOW $0.87
  • Resistance Level
  • SCYX $0.74
  • EPOW $0.95
  • Average True Range (ATR)
  • SCYX 0.04
  • EPOW 0.04
  • MACD
  • SCYX 0.00
  • EPOW -0.00
  • Stochastic Oscillator
  • SCYX 10.15
  • EPOW 19.54

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About EPOW Sunrise New Energy Co. Ltd

Sunrise New Energy Co Ltd is engaged in the manufacturing and sale of graphite anode material for EVs and other lithium-ion batteries. The Company's joint venture is in the construction of a manufacturing plant in Guizhou Province. The plant runs on inexpensive electricity from renewable sources that enables the group to be a low-cost and low environmental impact producer of graphite anode material, Its products include GS-1, GS-2, GS-3, GZD-1, GLD-1, and GZ-1.

Share on Social Networks: